Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 168.7% during mid-day trading on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.22 ($0.04). Approximately 61,345,711 shares changed hands during trading, an increase of 451% from the average daily volume of 11,133,673 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Price Performance
The company has a market capitalization of £13.43 million, a PE ratio of -322.40 and a beta of 1.53. The stock has a 50-day simple moving average of GBX 1.36 and a 200 day simple moving average of GBX 1.63.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- The 3 Best Fintech Stocks to Buy Now
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- With Risk Tolerance, One Size Does Not Fit All
- Why AMD Stock Might Already Be This Year’s Best Buy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
